ArticleBMC cardiovascular disorders2026
Plasma homocysteine and cardiovascular outcomes in postmenopausal women with coronary heart disease: a retrospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe association between plasma homocysteine (Hcy) and adverse cardiovascular outcomes in postmenopausal women with coronary heart disease (CHD) remains unclear. This study aimed to investigate the prognostic value of Hcy levels in this high-risk population.
methodsWe conducted a retrospective cohort study of 624 postmenopausal women with CHD from Ningxia Medical University General Hospital, with a 3-years follow-up. The association between Hcy and major adverse cardiovascular events (MACE) was evaluated using multivariate Cox regression. Non-linear relationships were assessed using generalized additive models (GAM) and threshold effect analyses. Survival disparities were analyzed via Kaplan-Meier estimates. Stratified analyses assessed association robustness, and receiver operating characteristic (ROC) curve analysis determined the predictive capacity of Hcy for MACE risk.
resultsDuring follow-up, 133 MACE occurred. Higher Hcy tertiles were associated with increased cumulative MACE risk (log-rank,P < 0.001). The multivariable cox regression revealed a significant positive relationship between Hcy and MACE risk. After full adjustment, each 1 µmol/L increment in Hcy was associated with a 17% increased risk of MACE (HR 1.17, 95%CI:1.12–1.22; P < 0.001). GAM analyses uncovered non-linear relationships (P for non-linearity < 0.05). Threshold analysis identified an inflection point at 11.28µmol/L. Subgroup analyses confirmed the robustness of this association (all P interaction > 0.05). ROC curve analysis demonstrated moderate predictive accuracy for Hcy (AUC 0.729, 95%CI: 0.682–0.777).
conclusionIn this retrospective cohort, Hcy may be independently associated with an increased risk of MACE in postmenopausal women with established CHD. These findings may suggest that Hcy could serve as a prognostic biomarker in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.